Bowel Resting Strategy May Not Reduce Mortality in C Diff Patients - Contagionlive.com
The bowel resting strategy might reduce switching from metronidazole to vancomycin among patients with Clostridioides difficile infection, but it might not reduce mortality or recurrence, a new study found.
Diversity of Circulating Clostridioides difficile Ribotypes in Mexico and Susceptibility to Fidaxomicin, Vancomycin, and Metronidazole
In this study, we report the results of the epidemiological analysis of Clostridioides difficile ribotypes (RTs) and antimicrobial susceptibility testing. Most isolates were RT027, representing 73% (84/115) of isolates. No isolates with reduced susceptibility to fidaxomicin were found; howeve …
Day-by-Day Management of the Inpatient With Moderate to Severe Inflammatory Bowel Disease
Hospitalization for inflammatory bowel disease is common and requires coordination of care. The goals of hospitalization are to markedly improve symptoms, transition management to an outpatient regimen, and prevent complications. Initially, providers should determine the phenotype and severity of di …
A Review of Clostridioides difficile Infection and Antibiotic-Associated Diarrhea
Antibiotic-associated diarrhea and Clostridioides difficile infection (CDI) occur frequently among adults. The pathophysiology of CDI is related to disruption of normal gut flora and risk factors include hospitalization, use of antibiotic therapy, and older age. Clinical manifestations can range fro …
New Adsorbent Protects Against C Diff for Patients with Hematologic Malignancies - MD Magazine
In results from a phase 2 trial show 7.5gm of DAV132 administered three times daily demonstrated protection against antibiotic-induced disruption of intestinal microbiota.
C. Difficile: Updates to Clinical Practice Guidelines - Pharmacy Times
Implications regarding how to properly treat patients with C. difficile infections based on data that have emerged since clinical practice guidelines were last updated.
1. C. Difficile Treatment: Fidaxomicin - Pharmacy Times
A discussion on fidaxomicin as treatment for C. difficile infections and clinician feedback on current challenges that impact its use in clinical practice.
Potent Compound May Effectively Treat C. Diff Reduce Recurrence - Pharmacy Times
Although clostridioides difficile is the leading cause of health care-associated infection in the United States, there are currently only 2 antibiotics available for its treatment: vancomycin and fidaxomicin.
Proteomic Adaptation of Clostridioides difficile to Treatment with the Antimicrobial Peptide Nisin
Clostridioides difficile is the leading cause of antibiotic-associated diarrhea but can also result in more serious, life-threatening conditions. The incidence of C. difficile infections in hospitals is increasing, both in frequency and severity, and antibiotic-resistant C. difficil …
Recent advances in the treatment of Clostridioides difficile infection: the ever-changing guidelines
Clostridioides difficile infection (CDI), formerly known as Clostridium difficile, continues to be the most common healthcare-associated infection worldwide. With the shifting epidemiology towards higher a incidence of community-acquired CDI and the continued burden on the healthcare s …
Diagnosis and management of Clostridioides difficile infection in patients with inflammatory bowel disease
CDI may complicate the course of IBD, however the presentation may not be typical. Therefore, all patients with worsening gastrointestinal symptoms should be evaluated for both CDI and IBD exacerbation. Providers should consider FMT for all patients with recurrent CDI as well as escalation of immuno …
Inflammatory Bowel Disease Presenting With Concurrent COVID-19 Multisystem Inflammatory Syndrome - American Academy of Pediatrics
Coronavirus disease 2019 is associated with a postinfectious multisystem inflammatory syndrome in children (MIS-C). This syndrome is marked by cytokine storm and multiorgan dysfunction, often affecting the gastrointestinal tract, the heart, and the hematopoietic system. We describe the case of a 16-year-old boy with an initial presentation of severe inflammatory bowel disease and concurrent MIS-C. He presented with abdominal pain, diarrhea, and hematochezia and met criteria for the systemic inflammatory response syndrome. Laboratory inflammatory profiling revealed markedly elevated ferritin...
American College of Gastroenterology Issues Updated Clinical Guidelines for C. difficile Infection - Newswise
Key guidance includes the diagnosis, management, and prevention of CDI, with a focus on diagnostic issues around diarrhea, distinguishing C. difficile colonizat
oColonic delivery of metronidazole-loaded capsules for local treatment of bacterial infections: a clinical pharmacoscintigraphy study
Drug delivery to the colon offers great promise for local treatment of colonic diseases as it allows bypassing systemic absorption in the small intestine, thereby increasing luminal drug concentrations in the colon. The primary objective of this in vivo pharmaco-scintigraphy study was to assess the …
Budget impact analysis of using procalcitonin to optimize antimicrobial treatment for patients with suspected sepsis in the intensive care unit and hospitalized lower respiratory tract infections in Argentina
Healthcare and financial benefits can be obtained by implementing procalcitonin-guided algorithms in Argentina. Although we found results to be robust on an aggregate level, some caution must be used when focusing only on sepsis patients in the intensive care unit.
Study Recommends Vancomycin as First-Line Treatment for Patients with C. Diff Infection and Inflammatory Bowel Disease - Pharmacy Times
Further, while there is ambiguity surrounding the treatment of IBD flare in patients with CDI, case reports suggest corticosteroid initiation after appropriate antibiotic therapy may be effective.
